Healthcare Biz Recap: Sanofi & Isis Get FDA Marketing Okay, Healthways Survives Report

Sanofi’s (NYSE:SNY) Genzyme company and Isis Pharmaceuticals (NASDAQ:ISIS) report that the FDA voted 9 to 6 in support of the marketing of Kynamro, or mipomersen sodium, in treating patients suffering from Homozygous Familial Hypercholesterolemia.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Shares of Healthways (NASDAQ:HWAY) plummet in early trading and then rebound following its third quarter beat on its bottom line and coming up short on revenue late Thursday. Net earnings fell by 47 percent year-over-year as revenue was impcted by the continued draw-down of a contract with Cigna Corp. (NYSE:CI). Additionally, the firm lowered its full-year earnings forecasts and reduced its sales view because of higher operational costs and reduced revenue from two contracts that were renewed early on.

Edwards Lifesciences (NYSE:EW) has seen the FDA expand the approved use of its heart valve to include patients suffering from aortic valve stenosis who although eligible for surgery, but are at high risk for serious complications or death.

Don’t Miss: How Healthy Are UnitedHealth and athenahealth?